BAP1 and neoplasm: We stained a subset of 28 tumours (Fig. 3a) with antibodies against BAP1 and MTAP (as a potential surrogate marker for CDKN2A deletion) along with PD-L1, VISTA, Ki-67 and an antibody for mitotic count (Fig. 3b-e).